(17.05.2023) While the global economy faces major economic ups and downs, the Swiss biotech industry is proving resilient. According to the Swiss Biotech Report 2023, the sector's turnover in 2022 amounted to CHF 6.8 billion.
Year-on-year, the industry recorded a growth of CHF 100 million. In addition, the sector was able to raise almost CHF 1.3 billion, of which CHF 550 million was invested in non-listed companies. The research and development (R&D) sector alone attracted investments of CHF 2.7 billion, a new record.
Listed companies managed to raise nearly CHF 780 million in 2022. The primary beneficiaries were VectivBio Holding (CHF 177 million), ADC Therapeutics (CHF 166 million) and MoonLake Immunotherapeutics (CHF 140 million). In addition, two companies in the sector went public on the SIX Swiss Exchange in 2022: Basel-based Kinarus Therapeutics and Zurich-based Xlife Sciences.
Switzerland's central location, excellent infrastructure and business-friendly environment make it a prime location for biotech companies. In 2022, one in five European biotech companies was based in Switzerland.
The Swiss Biotech Report also welcomes the creation of an innovation office within Swissmedic, the authority responsible for the approval and supervision of therapeutic products.
Last modification 17.05.2023
